medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2023, Number 2

<< Back Next >>

Medicina & Laboratorio 2023; 27 (2)

Diagnosis of von Willebrand disease

Mejía-Buriticá L, Pérez-Monterrosa ME, Vizcaíno-Carruyo JC

Language: Spanish
References: 52
Page: 139-155
PDF size: 308.93 Kb.


ABSTRACT

von Willebrand disease (VWD) is the most common hereditary bleeding disorder, and is characterized by a decreased ability of the von Willebrand factor (VWF) to bind to platelets and extracellular matrix collagen during primary hemostasis, due to quantitative or qualitative defects. VWD is classified into three main phenotypes: 1 and 3, which are quantitative disorders, and 2 (2A, 2B, 2M and 2N) that reflects qualitative disorders. Several steps are necessary for its diagnosis: 1) evaluation of the patient's personal and family bleeding history, 2) initial screening tests for bleeding disorders, 3) tests for the detection of VWD, 4) tests for the classification of VWD, and 5) molecular analysis. Both the subclassification of VWD and its diagnosis continue to represent important challenges, which we aimed to describe in this review, so that health professionals have a guide to assist them when they have patients with a bleeding disorder that requires exclusion of VWD, and implementation of an appropriate treatment.


REFERENCES

  1. Weyand AC, Flood VH. von Willebrand disease:Current status of diagnosis and management. HematolOncol Clin North Am 2021;35:1085-1101.https://doi.org/10.1016/j.hoc.2021.07.004.

  2. Tosetto A, Castaman G. How I treat type 2 variantforms of von Willebrand disease. Blood2015;125:907-914. https://doi.org/10.1182/blood-2014-08-551960.

  3. Baronciani L, Peyvandi F. How we make anaccurate diagnosis of von Willebrand disease.Thromb Res 2020;196:579-589. https://doi.org/10.1016/j.thromres.2019.07.010.

  4. Kreuz W. von Willebrand's disease: from discoveryto therapy - milestones in the last 25years. Haemophilia 2008;14:S1-2. https://doi.org/10.1111/j.1365-2516.2008.01846.x.

  5. Mannucci PM. Treatment of von Willebrand'sdisease. N Engl J Med 2004;351:683-694.https://doi.org/10.1056/NEJMra040403.

  6. Fogarty H, Doherty D, O'Donnell JS. Newdevelopments in von Willebrand disease. BrJ Haematol 2020;191:329-339. https://doi.org/10.1111/bjh.16681.

  7. Sladic M, Verdenik I, Smrkolj Š. The effectof von Willebrand Disease on pregnancy, delivery,and postpartum period: A retrospectiveobservational study. Medicina (Kaunas)2022;58. https://doi.org/10.3390/medicina58060774.

  8. Millar C. Why and how do we classify von Willebranddisease? Haemophilia 2015;21:407-410. https://doi.org/https://doi.org/10.1111/hae.12725.

  9. Budde U. Diagnosis of von Willebrand diseasesubtypes: implications for treatment. Haemophilia2008;14 Suppl 5:27-38. https://doi.org/10.1111/j.1365-2516.2008.01849.x.

  10. James PD, Connell NT, Ameer B, Di Paola J,Eikenboom J, Giraud N, et al. ASH ISTH NHFWFH 2021 guidelines on the diagnosis of vonWillebrand disease. Blood Adv 2021;5:280-300. https://doi.org/10.1182/bloodadvances.2020003265.

  11. World Federation of Hemophilia (WFH).Data collection. Report on the WFH AnnualGlobal Survey 2020. Québec, Cánada: WFH;2020. Acceso 12 de octubre de 2022. Disponibleen https://wfh.org/data-collection/.

  12. AlRahalNK. Inherited bleeding disorders iniraq and consanguineous marriage. Int J HematolOncol Stem Cell Res 2018;12:273-281.

  13. Wang X, Tang N, Lu Y, Hu Q, Li D. Two casesof von Willebrand disease type 3 in consanguineousChinese families. Mol Genet GenomicMed 2020;8:e1075. https://doi.org/10.1002/mgg3.1075.

  14. Borhany M, Pahore Z, Ul Qadr Z, Rehan M,Naz A, Khan A, et al. Bleeding disorders in thetribe: result of consanguineous in breeding.Orphanet J Rare Dis 2010;5:23. https://doi.org/10.1186/1750-1172-5-23.

  15. Stufano F, Baronciani L, Peyvandi F. Diagnósticode la enfermedad de von Willebrand:Caracterización fenotípica. Québec, Canadá:Federación Mundial de Hemofilia (FMH); 2017.Acceso 31 de octubre de 2022. Disponible enhttps://elearning.wfh.org/es/resource/diagnostico-de-la-enfermedad-de-von-willebrandcaracterizacion-fenotipica/.

  16. Sadler B, Castaman G, O'Donnell JS. vonWillebrand disease and von Willebrand factor.Haemophilia 2022;28 Suppl 4:S11-17. https://doi.org/10.1111/hae.14547.

  17. Swami A, Kaur V. von Willebrand disease:A concise review and update for thepracticing physician. Clin Appl ThrombHemost 2017;23:900-910. https://doi.org/10.1177/1076029616675969.

  18. LedfordKraemerMR. Analysis of von Willebrandfactor structure by multimer analysis.Am J Hematol 2010;85:510-514. https://doi.org/10.1002/ajh.21739.

  19. Zeng J, Shu Z, Liang Q, Zhang J, Wu W, WangX, et al. Structural basis of von Willebrand factormultimerization and tubular storage. Blood

  20. 2022;139:3314-3324. https://doi.org/10.1182/blood.2021014729.20. Laffan M, Sathar J, Johnsen JM. von Willebranddisease: Diagnosis and treatment,treatment of women, and genomic approachto diagnosis. Haemophilia 2021;27:S66-74.https://doi.org/10.1111/hae.14050.

  21. Yee A, Kretz CA. von Willebrand factor:form for function. Semin Thromb Hemost2014;40:17-27.

  22. Stockschlaeder M, Schneppenheim R,Budde U. Update on von Willebrand factormultimers: focus on high-molecular-weightmultimers and their role in hemostasis. BloodCoagul Fibrinolysis 2014;25:206-216. https://doi.org/10.1097/mbc.0000000000000065.

  23. Leebeek FW, Eikenboom JC. von Willebrand'sdisease. N Engl J Med 2016;375:2067-2080.https://doi.org/10.1056/NEJMra1601561.

  24. Kovacevic KD, Grafeneder J, SchörgenhoferC, Gelbenegger G, Gager G, FirbasC, et al. The von Willebrand factor A-1domain binding aptamer BT200 elevatesplasma levels of von Willebrand factor andfactor VIII: a first-in-human trial. Haematologica 2022;107:2121-2132. https://doi.org/10.3324/haematol.2021.279948.

  25. Sharma R, Flood VH. Advances in the diagnosisand treatment of von Willebrand disease.Blood 2017;130:2386-2391. https://doi.org/10.1182/blood-2017-05-782029.

  26. National Heart, Lung, and Blood Institute(NHLBI). The diagnosis, evaluation and managementof von Willebrand Disease (fullreport). Bethesda, Estados Unidos,: NHLBI;2007. Acceso 11 de octubre de 2022. Disponibleen https://www.nhlbi.nih.gov/resources/diagnosis-evaluation-and-management-vonwillebrand-disease-full-report.

  27. Goodeve A. Genetics of type 1 von Willebranddisease. Curr Opin Hematol2007;14:444-449. https://doi.org/10.1097/MOH.0b013e32826f4b41.

  28. Soto AV, Morales GM, Verdugo LP. Empleodel DDAVP en el manejo de la enfermedadde von Willebrand. Rev Chil Pediatr2005;76:193-197.

  29. Ng CJ, Di Paola J. von Willebrand disease:Diagnostic strategies and treatment options.Pediatr Clin North Am 2018;65:527-541.https://doi.org/10.1016/j.pcl.2018.02.004.

  30. KruseJarresR, Johnsen JM. How I treattype 2B von Willebrand disease. Blood2018;131:1292-1300. https://doi.org/10.1182/blood-2017-06-742692.

  31. Doruelo AL, Haberichter SL, ChristophersonPA, Boggio LN, Gupta S, Lentz SR, et al. Clinicaland laboratory phenotype variability in type2M von Willebrand disease. J Thromb Haemost2017;15:1559-1566. https://doi.org/10.1111/jth.13742.

  32. Seidizadeh O, Peyvandi F, Mannucci PM.von Willebrand disease type 2N: An update.J Thromb Haemost 2021;19:909-916. https://doi.org/10.1111/jth.15247.

  33. Castaman G. How I treat von Willebrand disease.Thromb Res 2020;196:618-625. https://doi.org/10.1016/j.thromres.2020.07.051.

  34. Makris M, Hermans C. The 2021 von Willebranddisease guidelines: Clarity and controversy.Haemophilia 2022;28:1-3. https://doi.org/10.1111/hae.14465.

  35. Lavin M, Christopherson P, Grabell J, AbshireT, Flood V, Haberichter SL, et al. Longitudinalbleeding assessment in von Willebrand diseaseutilizing an interim bleeding score. J ThrombHaemost 2022;20:2246-2254. https://doi.org/10.1111/jth.15807.

  36. Laffan MA, Lester W, O'Donnell JS, Will A,Tait RC, Goodeve A, et al. The diagnosis andmanagement of von Willebrand disease: aUnited Kingdom Haemophilia Centre DoctorsOrganization guideline approved by the BritishCommittee for Standards in Haematology.Br J Haematol 2014;167:453-465. https://doi.org/10.1111/bjh.13064.

  37. Nichols WL, Hultin MB, James AH, MancoJohnsonMJ, Montgomery RR, Ortel TL, etal. von Willebrand disease (VWD): evidencebaseddiagnosis and management guidelines,the National Heart, Lung, and Blood Institute(NHLBI) Expert Panel report (USA). Haemophilia2008;14:171-232. https://doi.org/10.1111/j.1365-2516.2007.01643.x.

  38. Kalot MA, Husainat N, El Alayli A, AbughanimehO, Diab O, Tayiem S, et al. von Willebrandfactor levels in the diagnosis of vonWillebrand disease: a systematic review andmeta-analysis. Blood Adv 2022;6:62-71. https://doi.org/10.1182/bloodadvances.2021005430.

  39. Castaman G, Linari S. Diagnosis and treatmentof von Willebrand disease and rare bleedingdisorders. J Clin Med 2017;6:45. https://doi.org/10.3390/jcm6040045.

  40. Bowman ML, James PD. Controversies in thediagnosis of type 1 von Willebrand disease. IntJ Lab Hematol 2017;39 Suppl 1:61-68. https://doi.org/10.1111/ijlh.12653.

  41. Seidizadeh O, Baronciani L, Pagliari MT,Cozzi G, Colpani P, Cairo A, et al. Phenotypicand genetic characterizations of the Milancohort of von Willebrand disease type 2.Blood Adv 2022;6:4031-4040. https://doi.org/10.1182/bloodadvances.2022007216.

  42. PracticalHaemostasis.com. von Willebrandfactor [VWF]: Introduction. Cambridge, UK:Sang Medicine Ltd; 2022. Acceso 11 de octubrede 2022. Disponible en https://practicalhaemostasis.com/Factor%20Assays/vwf/vwf_assays_introduction.html.

  43. Woods AI, Rossetti LC, Paiva J, De Brasi CD,Romero ML, Casinelli MM, et al. Type 2N vonWillebrand disease: Is it always a recessivetrait? Thromb Res 2021;198:49-51. https://doi.org/10.1016/j.thromres.2020.11.029.

  44. Gritsch H, Stimpfl M, Turecek PL. von Willebrandfactor multimer analysis by low resolutionSDS-agarose gel electrophoresis. Bio Protoc2022;12:e4495. https://doi.org/10.21769/BioProtoc.4495.

  45. Saadalla A, Seheult J, Pruthi RK, Chen D.von Willebrand factor multimer analysis andclassification: A comprehensive review andupdates. Semin Thromb Hemost 2022. [Epubahead of print] Sep 29 de 2022. https://doi.org/10.1055/s-0042-1757183.

  46. Favaloro EJ, Pasalic L, Curnow J. Type 2M andtype 2A von Willebrand disease: Similar but different.Semin Thromb Hemost 2016;42:483-497.

  47. Hermans C, Batlle J. Autosomal dominantvon Willebrand disease type 2M. ActaHaematol 2009;121:139-144. https://doi.org/10.1159/000214854.

  48. Frontroth JP, Favaloro EJ. Ristocetin-inducedplatelet aggregation (RIPA) and RIPA mixingstudies. Methods Mol Biol 2017;1646:473-494.https://doi.org/10.1007/978-1-4939-7196-1_35.

  49. Fels S, Boeckelmann D, Glonnegger H, BüchselM, Zieger B. Novel Likely PathogenicVariant in the A3 Domain of von WillebrandFactor Leading to a Collagen-Binding Defect.Hamostaseologie 2022. https://doi.org/10.1055/a-1701-2181.

  50. Goodeve A. Diagnosing von Willebrand disease:genetic analysis. Hematology Am Soc HematolEduc Program 2016;2016:678-682. https://doi.org/10.1182/asheducation-2016.1.678.

  51. Flood VH, Garcia J, Haberichter SL. The roleof genetics in the pathogenesis and diagnosisof type 1 von Willebrand disease. CurrOpin Hematol 2019;26:331-335. https://doi.org/10.1097/moh.0000000000000524.

  52. Adil SN, Qureshi A. von Willebrand disease-An under diagnosed entity. J Pak Med Assoc2008;58:157-158.




2020     |     www.medigraphic.com